Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Angiogenesis Stories

2013-11-14 08:33:02

ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and nine-month periods ending September 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) EntreMed reported a net loss for the third quarter of 2013 of ($1.4 million), or ($0.05) per share. This compares with a net loss of ($1.2...

2013-11-07 08:33:13

The Angiogenesis Foundation was awarded with the highest "4-star" rating from a premiere charity evaluator for good governance, sound fiscal management, transparency and accountability. CAMBRIDGE, Mass., Nov. 7, 2013 /PRNewswire-USNewswire/ -- The Angiogenesis Foundation has received the highest rating of four out of four possible stars from Charity Navigator--a prominent and independent evaluator of charities. This rating demonstrates the Foundation's commitment to good governance,...

2013-11-05 10:55:56

Study confirms that vascular normalization is the way these drugs improve patient survival Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital (MGH) researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly 'normalized' abnormal blood vessels around their...

2013-10-31 23:29:18

ResearchMoz include new market research report "Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports. Click Here For Download Detail Report - http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html Albany, NY (PRWEB) October 31, 2013 Macular...

2013-10-29 20:22:35

PARSIPPANY, N.J., Oct. 29, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with Opthea Pty Ltd of Melbourne, Australia. The contract covers process development and cGMP manufacture by DSM for Opthea's lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel...

2013-10-28 08:30:17

CLEVELAND, Oct. 28, 2013 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held clinical-stage company developing novel therapies for treatment of cardiovascular disease, announced today that the company has completed enrollment of the STOP-HF trial. STOP-HF is a double-blinded, placebo-controlled, multi-center trial of its non-viral DNA plasmid therapy JVS-100 for patients with symptomatic heart failure. A total of 93 patients have been enrolled in this trial at 16...

2013-10-17 12:30:28

Clinical data demonstrate CRLX101 is well suited for combination therapy CAMBRIDGE, Mass., Oct. 17, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that a poster on the combinability and efficacy data of Cerulean's Phase 2 candidate, CRLX101, has been selected as one of the top posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and will be one of four posters...

2013-10-15 12:52:40

Researchers at the University of Illinois at Chicago have identified a protein expressed by human bone marrow stem cells that guides and stimulates the formation of blood vessels. Their findings, which could help improve the vascularization of engineered tissues, were reported online Oct. 12 in the Journal of Molecular and Cellular Cardiology. “Some stem cells actually have multiple jobs,” says Dr. Jalees Rehman, associate professor of cardiology and pharmacology at the UIC College...

2013-10-03 09:31:58

The phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumor growth, prolonging survival of patients with advanced gastric cancer This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10...

2013-10-02 10:34:29

Treatment with losartan increases drug delivery in animal models by opening collapsed tumor blood vessels Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In their report in the online journal Nature Communications, Massachusetts General Hospital (MGH) investigators describe how the angiotensin inhibitor losartan improved the delivery of chemotherapy drugs and oxygen throughout...